Get started

Rossy Cancer Network

Alternate name: Réseau de cancérologie Rossy
ROR: 00f3ctm49
OpenAlex ID: I4405278727
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
2020 · K. Esfahani, L. Roudaia, et al. · Current Oncology · 1,006
PDF
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
2019 · Jordi Rodon, Jean-Charles Soria, et al. · Nature Medicine · 598
Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
2022 · David M. O'Malley, Giovanni Mendonca Bariani, et al. · Journal of Clinical Oncology · 537
PDF
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
2019 · Hyun Cheol Chung, Sarina A. Piha-Paul, et al. · Journal of Thoracic Oncology · 423
Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors
2019 · Arielle Elkrief, Layal El Raichani, et al. · OncoImmunology · 216
PDF
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
2018 · Hyun Cheol Chung, Jose A. Lopez-Martin, et al. · Journal of Clinical Oncology · 197
Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
2019 · Khashayar Esfahani, Tho-Alfakar Al-Aubodah, et al. · Nature Communications · 114
PDF
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
2020 · Antoni Ribas, Alain Algazi, et al. · Nature Communications · 93
PDF
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
2017 · Teresa M. Petrella, Caroline Robert, et al. · European Journal of Cancer · 91
MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma
2017 · Yao Zhan, Jun Guo, et al. · Journal of Clinical Investigation · 77
Rehabilitation and Exercise Oncology Program: Translating Research into a Model of Care
2017 · Mary-Ann Dalzell, N. Smirnow, et al. · Current Oncology · 76
PDF
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study
2023 · Do‐Youn Oh, Alain Algazi, et al. · Cancer · 67
PDF
Adverse events associated with immune checkpoint inhibitor treatment for cancer
2019 · Khashayar Esfahani, Nicholas Meti, et al. · Canadian Medical Association Journal · 66
PDF
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
2017 · Rahima Jamal, Réjean Lapointe, et al. · Journal for ImmunoTherapy of Cancer · 55
PDF
The MNK1/2–eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer
2021 · Qianyu Guo, Margarita Bartish, et al. · Cancer Research · 47
PDF
The nurse pivot-navigator associated with more positive cancer care experiences and higher patient satisfaction
2020 · Carmen G. Loiselle, Samar Attieh, et al. · Canadian Oncology Nursing Journal · 43
PDF
Lung Cancer Care Trajectory at a Canadian Centre: An Evaluation of How Wait Times Affect Clinical Outcomes
2017 · G. Kasymjanova, D. Small, et al. · Current Oncology · 42
PDF
A Pilot Randomized Controlled Trial on the Effects of a Progressive Exercise Program on the Range of Motion and Upper Extremity Grip Strength in Young Adults With Breast Cancer
2017 · Marize Ibrahim, Thierry Muanza, et al. · Clinical Breast Cancer · 42
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer
2017 · Stephen K. Chia, Susan L. Ellard, et al. · Breast Cancer Research · 38
PDF
The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma
2020 · Sathyen A. Prabhu, Omar Moussa, et al. · International Journal of Molecular Sciences · 36
PDF
Translation of cancer immunotherapy from the bench to the bedside
2019 · Qianyu Guo, Fan Huang, et al. · Advances in cancer research · 35
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results
2025 · David M. O'Malley, Giovani M. Bariani, et al. · Gynecologic Oncology · 31
Time course of upper limb function and return-to-work post-radiotherapy in young adults with breast cancer: a pilot randomized control trial on effects of targeted exercise program
2017 · Marize Ibrahim, Thierry Muanza, et al. · Journal of Cancer Survivorship · 28
Identification of Performance Indicators across a Network of Clinical Cancer Programs
2016 · S.R. Khare, G. Batist, et al. · Current Oncology · 27
PDF
Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
2022 · Michael Schenker, Mauricio Burotto, et al. · Cancer Research · 26
Works count: 76
Citation count: 10,320
Year
Topic
Type